About: Capmatinib     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Drug, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FCapmatinib

Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR, as detected by an FDA-approved test. The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

AttributesValues
rdf:type
rdfs:label
  • Capmatinib (en)
  • Capmatinib (de)
  • カプマチニブ (ja)
rdfs:comment
  • Capmatinib ist ein Arzneistoff aus der Gruppe der Tyrosinkinase-Hemmer, der zur Behandlung einer bestimmten Form des nicht-kleinzelligen Lungenkrebses (NSCLC) verwendet wird. Unter dem Namen Tabrecta (Hersteller: Novartis) wurde er erstmals 2020 in den USA zugelassen. Die Anwendung erfolgt oral (Einnahme). (de)
  • カプマチニブ（Capmatinib）は成人の転移性非小細胞肺癌（NSCLC）に対する治療薬である。中でも、膜受容体肝細胞増殖因子受容体（HGFR）をコードするMET 遺伝子のエクソン14をスキップする変異を有するものを対象とする。 主な副作用には末梢性浮腫、吐き気、疲労、嘔吐、呼吸困難、食欲減退などがある。 NSCLCは肺癌全体の90%が属する最も一般的な肺癌であり、転移を起こす危険性が高い。MET エクソン14スキップは癌が転移に至る重要な段階の一つであると認識されており、肺癌患者の3-4%にこの変異が認められる。カプマチニブは米国において、この変異を有する非小細胞肺癌の治療のため承認された初めての治療薬である（日本ではに続く2例目）。 (ja)
  • Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR, as detected by an FDA-approved test. The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite. (en)
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/Capmatinib.svg
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
thumbnail
ATC suffix
  • EX17 (en)
ATC prefix
  • L01 (en)
c
CAS number
ChEMBL
ChemSpiderID
DrugBank
  • DB11791 (en)
F
H
KEGG
  • D10696 (en)
  • D10891 (en)
legal US
  • Rx-only (en)
MedlinePlus
  • a620038 (en)
n
O
pregnancy category
  • Not recommended (en)
PubChem
routes of administration
SMILES
  • CNCc1ccccc1F (en)
StdInChI
StdInChIKey
  • LIOLIMKSCNQPLV-UHFFFAOYSA-N (en)
synonyms
  • INC280 (en)
tradename
  • Tabrecta (en)
UNII
  • TY34L4F9OZ (en)
has abstract
  • Capmatinib ist ein Arzneistoff aus der Gruppe der Tyrosinkinase-Hemmer, der zur Behandlung einer bestimmten Form des nicht-kleinzelligen Lungenkrebses (NSCLC) verwendet wird. Unter dem Namen Tabrecta (Hersteller: Novartis) wurde er erstmals 2020 in den USA zugelassen. Die Anwendung erfolgt oral (Einnahme). (de)
  • Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR, as detected by an FDA-approved test. The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite. Non-small cell lung cancer (NSCLC) is a disease in which malignant cancer cells form in the tissues of the lung. It is the most common type of lung cancer with up to 90% of all lung carcinomas falling into the non-small cell category. NSCLC occurs when healthy cells become abnormal and grow rapidly. One danger of this form of cancer is that there's a high likelihood that the cancer cells will spread from the lungs to other organs and body parts. Cancer metastasis consists of a sequential series of events, and MET exon 14 skipping is recognized as a critical event for metastasis of carcinomas. Mutations leading to MET exon 14 skipping are found in 3-4% of people with lung cancer. Capmatinib is the first therapy approved by the US Food and Drug Administration (FDA) to treat non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping). (en)
  • カプマチニブ（Capmatinib）は成人の転移性非小細胞肺癌（NSCLC）に対する治療薬である。中でも、膜受容体肝細胞増殖因子受容体（HGFR）をコードするMET 遺伝子のエクソン14をスキップする変異を有するものを対象とする。 主な副作用には末梢性浮腫、吐き気、疲労、嘔吐、呼吸困難、食欲減退などがある。 NSCLCは肺癌全体の90%が属する最も一般的な肺癌であり、転移を起こす危険性が高い。MET エクソン14スキップは癌が転移に至る重要な段階の一つであると認識されており、肺癌患者の3-4%にこの変異が認められる。カプマチニブは米国において、この変異を有する非小細胞肺癌の治療のため承認された初めての治療薬である（日本ではに続く2例目）。 (ja)
DailyMedID
  • Capmatinib (en)
legal CA
  • Rx-only (en)
legal EU
  • Rx-only (en)
prov:wasDerivedFrom
page length (characters) of wiki page
alternative name
  • Tabrecta (en)
CAS number
  • 1029712-80-8
ChEMBL
  • 3188267
DrugBank
  • DB11791
FDA UNII code
  • TY34L4F9OZ
KEGG
  • D10696
  • D10891
MedlinePlus
  • a620038
PubChem
  • 25145656
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 59 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software